|
||||
| European Medicines Agency implements internal reorganisation |
The European Medicines Agency has begun implementing a series of changes to its internal organisation aimed at improving the functioning of the Agency and the way in which it delivers its core tasks. The changes will be introduced gradually from September to December 2009.
In line with its increased responsibilities, the Agency has developed over the past years in terms of staff numbers and internal processes. The number of scientific committees and the complexity of procedures have also grown, and the cross-relationship between committees brings with it the need for enhanced coordination. In addition, future legislative proposals are expected to bring further responsibilities to the Agency.
Following an Agency-wide process improvement exercise initiated in 2006, from May 2007 attention focused specifically on core business - examining processes within the two units dealing with medicinal products for human use and monitoring their interactions in order to assess their potential for adapting to future needs.
The resulting reorganisation includes the following key changes:
- creation of a single Sector responsible for all areas of veterinary medicines - development, evaluation and maintenance of veterinary medicines, public and animal health (including safety) and veterinary regulatory affairs - creation of a single Sector for the management of product data and documentation related to applications for the whole Agency; it will also be involved in the development of IT systems to support scientific business processes Rationalisation of services within the Unit for Information and Communications Technology, led by Hans-Georg Wagner and within the Administration Unit, led by Andreas Pott |




The European Medicines Agency has begun implementing a series of changes to its internal organisation aimed at improving the functioning of the Agency and the way in which it delivers its core tasks. The changes will be introduced gradually from September to December 2009.
In line with its increased responsibilities, the Agency has developed over the past years in terms of staff numbers and internal processes. The number of scientific committees and the complexity of procedures have also grown, and the cross-relationship between committees brings with it the need for enhanced coordination. In addition, future legislative proposals are expected to bring further responsibilities to the Agency.
Following an Agency-wide process improvement exercise initiated in 2006, from May 2007 attention focused specifically on core business - examining processes within the two units dealing with medicinal products for human use and monitoring their interactions in order to assess their potential for adapting to future needs.
The resulting reorganisation includes the following key changes:

